Translator：Wang Qiyu

In November 2023, Shanghai Landing Law Offices, at the request of the listed company Rongchang Biopharmaceuticals (Yantai) Co., Ltd. (referred to as "Rongchang Biopharma"), provided specialized legal services for its equity incentive plan. The legal services were carried out by the legal team led by Lawyer Zhang Xiaoying. Specific project details are as follows:

Rongchang Biopharma, with the stock code 688331, was established on July 4, 2008. It was listed and traded on the Main Board of the Hong Kong Stock Exchange on November 9, 2020, and subsequently listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on March 31, 2022. The company is headquartered in Yantai City, Shandong Province, China, and has research institutions and offices in both China and the United States. Rongchang Biopharma is dedicated to the discovery, development, production, and commercialization of innovative biopharmaceuticals with significant clinical value in major disease areas such as autoimmune disorders, oncology, and ophthalmology.

Lawyer Zhang Xiaoying's team conducted a thorough examination and verification of relevant matters related to Rongchang Biopharma's A-share restricted stock incentive plan for the year 2023 (draft) in accordance with relevant laws and regulations. They issued a legal opinion based on their diligent approach, professional knowledge, and extensive practical experience, earning the trust and full affirmation of the client.